Beta Bionics Upsizes Offering to $150M; Stock Slides 5.8%
BBNX has more than doubled off its 52-week low of $8.8.
Summary
Beta Bionics priced its public offering at $17.25 per share, a discount to the last close, and upsized gross proceeds to $150 million from the previously proposed $125 million. The stock fell 5.8% to $18.11 in premarket trading, adding to a 37% year-to-date decline. The offering includes pre-funded warrants and a 30-day underwriter option for 1.3 million additional shares, increasing potential dilution. Proceeds will fund commercialization of the recently FDA-cleared Mint patch pump. The offering is expected to close September 17.
At the time of this announcement, BBNX was trading at $18.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $865.2M. The 52-week trading range was $8.80 to $32.71. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.